Financial insights of SXTP

MyFinsight

For the year ending 2025-12-31, SXTP made $1,005,471 in revenue. -$7,365,158 in net income. Net profit margin of -732.51%.

Income Statement	2025-12-31	2024-12-31
Product revenues net of discounts and rebates	1,005,471	607,574
Cost of revenues	781,695	384,765
Gross profit	223,776	222,809
Research revenues	403,624	73,771
Net revenue	627,400	296,580
Research and development	2,106,156	4,986,526
General and administrative expenses	6,279,823	5,024,985
Total operating expenses	8,385,979	10,011,511
Loss from operations	-7,758,579	-9,714,931
Interest expense	7,805	7,912
Change in fair value of derivative liabilities	266,089	-1,665,966
Other income, net	131,970	101,464
Total interest and other income (expense), net	390,254	1,759,518
Loss from operations before provision for income taxes	-7,368,325	-7,955,413
Provision for income taxes (note 9)	0	250
Net loss	-7,368,325	-7,955,663
Net loss noncontrolling interest	-3,167	-8,556
Net loss attributed to 60 degrees pharmaceuticals, inc	-7,365,158	-7,947,107
Cumulative dividends on series a preferred stock	-	483,301
Unrealized foreign currency translation (loss) gain	-	-90
Net loss - attributed to common stockholders	-	-8,430,498

Basic EPS	-11.73	-18.55
Diluted EPS	-11.73	-18.55
Basic Average Shares	670,211	454,582
Diluted Average Shares	670,211	454,582